Advertisement

Parasitology Research

, Volume 113, Issue 2, pp 555–564 | Cite as

Pyrimethamine-loaded lipid-core nanocapsules to improve drug efficacy for the treatment of toxoplasmosis

  • Kenia Pissinate
  • Érica dos Santos Martins-Duarte
  • Scheila Rezende Schaffazick
  • Catiúscia Padilha de Oliveira
  • Rossiane Cláudia Vommaro
  • Sílvia Stanisçuaski Guterres
  • Adriana Raffin Pohlmann
  • Wanderley de Souza
Original Paper

Abstract

We propose an innovative product based on the nanoencapsulation of pyrimethamine (PYR), aiming an improvement of drug efficacy for the treatment of toxoplasmosis. The in vitro cytotoxicity effect of encapsulated PYR and PYR-colloidal suspension was concomitantly evaluated against LLC-MK2 lineage and mouse peritoneal macrophage showing that the cells had similar tolerance for both PYR encapsulated or in the aqueous suspension. CF1 mice acutely infected with tachyzoites of Toxoplasma gondii RH strain treated with different doses (5.0–10 mg/kg/day) of PYR-nanocapsules had survival rate higher than the animals treated with the same doses of non-encapsulated PYR. Thus, encapsulation of PYR improved the efficacy of this drug against an acute model of toxoplasmosis in mice and can be considered an alternative for reducing the dose of PYR, which, in turn, could also reduce the side effects associated to the treatment.

Keywords

Encapsulation Efficiency Toxoplasmosis Polysorbate Pyrimethamine Atovaquone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors thank Mr. Helcio Evangelista da Silva for technical assistance with animal care, Dr. Daniel Gonçalves for technical assistance with FESEM and Dr. Eduardo José Torres and Dr. Kildare Miranda for helpful discussions. The authors would like to thank Perstorp for kindly providing the CAPA® 6500 product. This work was supported by Rede Nanobiotec-Brazil CAPES, Grants CNPq/MCT, and Fellows CAPES. Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Programa de Núcleos de Excelência-Pronex-FAPERJ-CNPq and Pronex FAPERGS-CNPq (#10/0048-4).

References

  1. Anderson AC (2005) Targeting DHFR in parasitic protozoa. Drug Discov Today 10:121–128PubMedCrossRefGoogle Scholar
  2. Bernardi A, Braganhol E, Jäger E, Figueiró F, Edelweiss MI, Pohlmann AR, Guterres SS, Battastini AM (2009) Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 281:53–63PubMedCrossRefGoogle Scholar
  3. Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AM, Pohlmann AR, Guterres SS, Salbego CG (2012) Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine 7:4927–42PubMedCentralPubMedCrossRefGoogle Scholar
  4. Boca MB, Apostolides Z, Pretorius E (2005) A validated HPLC method for determining residues of a dual active ingredient anti-malarial drug on manufacturing equipment surfaces. J Pharm Biomed Anal 37:461–468PubMedCrossRefGoogle Scholar
  5. Bordes C, Snabre P, Frances C, Biscans B (2002) Optical investigation of shear- and time-dependent microstructural changes to stabilize and depletion-flocculated concentrated latex sphere suspensions. Powder Technol 128:218–228CrossRefGoogle Scholar
  6. Chio LC, Queener SF (1993) Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother 37:1914–1923PubMedCentralPubMedCrossRefGoogle Scholar
  7. Couvreur P, Barrat G, Fattal E, Legrand P, Vauthier C (2002) Nanocapsule technology: a review. Crit Rev Ther Drug 19:99–134CrossRefGoogle Scholar
  8. De Araújo MGV, Vieira EKB, Lázaro GS, Conegero LS, Ferreira OP, Almeida LE, Barreto LS, da Costa NB, Jr GIF (2007) Inclusion complexes of pyrimethamine in 2-ydroxypropyl-b-cyclodextrin: characterization, phase solubility and molecular modeling. Bioorg Med Chem 15:5752–5759PubMedCrossRefGoogle Scholar
  9. Friedrich RB, Fontana MC, Beck RCR, Pohlmann AR, Guterres SS (2008) Development and physicochemical characterization of dexamethasone-loaded polymeric nanocapsule suspensions. Quim Nova 31(5):1131–36CrossRefGoogle Scholar
  10. Gangjee A, Jain HD, Queener SF, Kisliuk RL (2008) The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents. J Med Chem 51:4589–600PubMedCrossRefGoogle Scholar
  11. Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration; a guide for clinicians. CMAJ 172:367–79PubMedCentralPubMedCrossRefGoogle Scholar
  12. Goldsmith M, Mizrahy S, Peer D (2011) Grand challenges in modulating the immune response with RNAi nanomedicines. Nanomedicine 6:1771–1785PubMedCrossRefGoogle Scholar
  13. Jornada DS, Fiel LA, Bueno K, Gerent JF, Petzhold CL, Beck RCR, Guterres SS, Pohlmann AR (2012) Lipid-core nanocapsules: mechanism of self-assembly, control of size and loading capacity. Soft Matter 8:6646–6655CrossRefGoogle Scholar
  14. Keck CM, Muller RH (2008) Size analysis of submicron particles by laser diffractometry—90% of the published measurements are false. Int J Pharm 355:150–163PubMedCrossRefGoogle Scholar
  15. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363:1965–1976PubMedCrossRefGoogle Scholar
  16. Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142PubMedCrossRefGoogle Scholar
  17. Müller RH, Petersen RD, Hommoss A, Pardeike J (2007) Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–530PubMedCrossRefGoogle Scholar
  18. Nissapatorn V, Sawangjaroen N (2011) Parasitic infections in HIV infected individuals: diagnostic & therapeutic challenges. Indian J Med Res 134:878–97PubMedCrossRefGoogle Scholar
  19. Oliveira CP, Venturini CG, Donida B, Poletto FS, Guterres SS, Pohlmann AR (2012) An algorithm to determine the mechanism of drug distribution in lipid-core nanocapsule formulations. Soft Matter 9:1141–2012CrossRefGoogle Scholar
  20. Pohlmann AR, Fonseca FN, Paese K, Detoni CB, Coradini K, Beck RCR, Guterres SS (2013) Poly(ε-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv. doi: 10.1517/17425247.2013.769956
  21. Poletto FS, Fiel LA, Lopes MV, Schaab G, Gomes AMO, Guterres SS, Rossi-Bergmann B, Pohlmann AR (2012) Fluorescent-labeled poly(ε-caprolactone) lipid-core nanocapsules: synthesis, physicochemical properties and macrophage uptake. J Colloid Sci Biotechnol 1:89–98CrossRefGoogle Scholar
  22. Poletto FS, Jäger E, Cruz L, Pohlmann AR, Guterres SS (2008) The effect of polymeric wall on the permeability of drug-loaded nanocapsules. Mater Sci Eng C Mater Biol Appl 28:472CrossRefGoogle Scholar
  23. Prieto MJ, Bacigalupe D, Pardini O, Amalvy JI, Venturini C, Morilla MJ, Romero EL (2006) Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. Int J Pharm 326:160–168PubMedCrossRefGoogle Scholar
  24. Sahay G, Alakhova DY, Kabanov AV (2010) Endocytosis of nanomedicines. J Control Release 145:182–195PubMedCentralPubMedCrossRefGoogle Scholar
  25. Schnell JR, Dyson HJ, Wright PE (2004) Structure, dynamics, and catalytic function of dihydrofolate reductase. Annu Rev Biophys Biomol Struct 33:119–140PubMedCrossRefGoogle Scholar
  26. Shubar HM, Lachenmaier S, Heimesaat MM, Lohman U, Mauludin R, Mueller RH, Fitzner R, Borner K, Liesenfeld O (2011) SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers. J Drug Target 19:114–124PubMedCrossRefGoogle Scholar
  27. Sordet F, Aumjaud Y, Fessi H, Derouin F (1998) Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite 5:223–9PubMedGoogle Scholar
  28. Venturini CG, Jäger E, Oliveira CP, Bernardi A, Battastini AMO, Guterres SS (2011) Formulation of lipid core nanocapsules. Colloid Surf A 375:200–208CrossRefGoogle Scholar
  29. Weniger H (1979) Review of side effects and toxicity of pyrimethamine. Geneva: World health Organization; WHO/MAL/79907Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Kenia Pissinate
    • 1
    • 4
  • Érica dos Santos Martins-Duarte
    • 1
    • 2
  • Scheila Rezende Schaffazick
    • 1
    • 3
  • Catiúscia Padilha de Oliveira
    • 3
  • Rossiane Cláudia Vommaro
    • 1
    • 2
  • Sílvia Stanisçuaski Guterres
    • 3
  • Adriana Raffin Pohlmann
    • 3
    • 4
  • Wanderley de Souza
    • 1
    • 2
    • 5
  1. 1.Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas FilhoUniversidade Federal do Rio de JaneiroRio de JaneiroBrazil
  2. 2.Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e BioimagensUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  3. 3.Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de FarmáciaUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  4. 4.Departamento de Química Orgânica, Instituto de QuímicaUniversidade Federal do Rio Grande do SulPorto AlegreBrazil
  5. 5.Instituto Nacional de Metrologia e Qualidade Industrial—InmetroRio de JaneiroBrazil

Personalised recommendations